Sepsis News and Research

Latest Sepsis News and Research

HSMR helps identify sepsis as an area of concern for Canadian hospitals

A new study shows that in 2008-2009 more than 9,300 patients died of sepsis, a condition resulting from the body's response to severe infection, in Canadian hospitals outside Quebec.

11 Dec 2009

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

In a large Phase III clinical trial, Tasigna (nilotinib capsules) demonstrated greater efficacy over Gleevec (imatinib) in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The new clinical data were just presented as a late breaking abstract at the 51st annual meeting of the American Society of Hematology (ASH), in New Orleans, Louisiana.

11 Dec 2009

New evidence finds link between nutrition, obesity and immune system

Fresh evidence that fatty food is bad for our health has come to light: mice fed a lard-based diet over a long period got worse at fighting bacteria in the blood, reveals a thesis from the Sahlgrenska Academy at the University of Gothenburg.

8 Dec 2009

Deaths from opioid use in Ontario have doubled, according to new study

Deaths from opioid use in Ontario have doubled-from 13.7 deaths per million residents in 1991 to 27.2 deaths per million residents in 2004-according to a new study led by physicians at St. Michael's Hospital and the Institute for Clinical Evaluative Sciences (ICES) in Toronto.

8 Dec 2009

New data from Allos Therapeutics' FOLOTYN trial for PTCL

Allos Therapeutics, Inc. today reported a new analysis of data from the Company’s pivotal PROPEL trial of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated.

7 Dec 2009

Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting

Gloucester Pharmaceuticals announced today the presentation of positive data from an analysis of ISTODAX® (romidepsin) in a subset of patients from Gloucester’s registration study in cutaneous T-cell lymphoma (CTCL) at the 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, LA.

7 Dec 2009

Presentation of preclinical data demonstrating the combination of ISTODAX and Velcade announced

Gloucester Pharmaceuticals announced today the presentation of preclinical data demonstrating that the combination of ISTODAX® (romidepsin) and Velcade® (bortezomib) resulted in synergistic anti-tumor activity in B-cell non-Hodgkin's lymphoma cell lines.

7 Dec 2009

New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported

Allos Therapeutics, Inc. today reported new analyses of data from the Company’s pivotal PROPEL trial of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

7 Dec 2009

Positive final data from Phase 2 study of ISTODAX presented

Gloucester Pharmaceuticals announced today the presentation of positive final data from a Phase 2 study of ISTODAX® (romidepsin) in peripheral T-cell lymphoma (PTCL) conducted by the National Cancer Institute (NCI) at the 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, LA.

6 Dec 2009

Allos Therapeutics, Idis collaborate in named patient program for FOLOTYN

Allos Therapeutics, Inc. today announced the execution of a collaborative agreement with Idis, a UK-based global company, to manage the named patient program for FOLOTYN™ (pralatrexate injection) outside of the United States. The U.S. Food and Drug Administration (FDA) has granted accelerated approval for FOLOTYN for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

4 Dec 2009

ISTODAX included in the updated NCCN Clinical Practice Guidelines in Oncology

Gloucester Pharmaceuticals announced today that ISTODAX® (romidepsin) has been included in the updated National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology™ as a suggested systemic treatment option for patients with mycosis fungoides and Sézary syndrome—two of the most common types of cutaneous T-cell lymphoma (CTCL).

4 Dec 2009

PEG polymer may prevent GI injury during cancer radiotherapy

A non-absorbed, oral co-polymer therapy under development by Midway Pharmaceuticals demonstrated the ability to protect against damage to healthy gastrointestinal tissues and to prevent lethal bacterial infections in animal models of radiation damage.

3 Dec 2009

Sepsis, a serious infection, remains a major threat to 'late preterm' infants

Sepsis is a serious infection that is a major cause of death in very premature infants. But sepsis is also a threat in "late preterm" infants born just a few weeks prematurely, according to a study in the December issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

3 Dec 2009

MSC's Quality Initiative Programs to be highlighted at the 2009 IHI National Forum

Medical Simulation Corporation (MSC) will highlight its full menu of Quality Initiative Programs at the 2009 IHI National Forum, December 7-9, 2009, in Orlando, Florida. MSC is the first simulation company to introduce simulation-based education programs that help healthcare providers bridge the gap between measurement and achievement of publicly reported patient safety and quality initiatives.

2 Dec 2009

Infections remain a common problem in ICU patients

An international study that examined the extent of infections in nearly 1,300 intensive care units (ICUs) in 75 countries found that about 50 percent of the patients were considered infected, with infection associated with an increased risk of death in the hospital, according to a study in the December 2 issue of JAMA.

2 Dec 2009

Allos Therapeutics granted U.S. patent for FOLOTYN

Allos Therapeutics, Inc. today announced that the United States Patent and Trademark Office has issued a patent for the use of FOLOTYN™ (pralatrexate injection) for the treatment of T-cell lymphoma. U.S. Patent No. 7,622,470 was issued to Memorial-Sloan Kettering Cancer Center, SRI International and Southern Research Institute, and expires on November 24, 2025.

30 Nov 2009

Community-based program proves to be successful in reducing skin infections in Australian aboriginal children

A community-based program aimed at reducing the burden of skin disease across remote communities in Australia's Northern Territory has been successful according to a study published November 24 in the open-access journal PLoS Neglected Tropical Diseases.

25 Nov 2009

Comparison study finds no significant differences in post-transplant survival rates of NASH and ETOH groups

Researchers at the University of Miami School of Medicine compared the outcomes of cirrhotic patients who underwent liver transplants for nonalcoholic steatohepatitis (NASH) versus alcoholic liver disease (ETOH) and found no statistically significant differences in post-transplant survival rates between the NASH and ETOH groups

25 Nov 2009

GMC’s AICU nurses honored with Beacon Award for Critical Care Excellence

Geisinger Medical Center's Adult Intensive Care Unit (AICU) nurses were recently recognized with the Beacon Award for Critical Care Excellence. Created by the American Association of Critical Care Nurses (AACN), the award recognizes adult critical care, adult progressive care and pediatric critical care units that achieve high-quality outcomes and exemplify excellence in professional practice, patient care and outcomes.

24 Nov 2009

Medical students and biomedical scientists to attend 8th World Congress on Trauma, Shock, Inflammation and Sepsis

The 8th World Congress on Trauma, Shock, Inflammation and Sepsis – TSIS 2010 – will take place from March 9th to13th 2010 in the Auditorium Tract of the Ludwig-Maximilians-University, Campus Grosshadern, in Munich/Germany.

23 Nov 2009